Zika virus used to treat aggressive brain cancer
October 2, 2017
The 8-Week Cure for Hepatitis C | Infectious Diseases 
October 3, 2017
Show all

Cost of Hepatitis C Antivirals May Keep Patients Away

Treating hepatitis C comes with a high price tag.

Only one-quarter of patients worldwide with the chronic hepatitis C virus (HCV) received antiviral treatment before the widespread use of direct-acting antiviral (DAA) drugs, a review that considered almost 500,000 people has found.

But the authors conclude that treatment rates should improve in the interferon-free era, although the costs of DAA therapy could limit participation.

“The number of patients eligible for treatment will increase significantly as DAA therapies are recommended now in patients with decompensated cirrhosis,” Philip Vutien, MD, one of the study’s authors from Stanford University Medical Center, Palo Alto, California, said. “In addition, as DAA therapies are much better tolerated, we would expect patients and their providers to be much more willing to initiate treatment.”

Vutien and a team from Stanford and Kaohsiung Medical University in Taiwan reviewed data from published reports, liver meetings and other primary sources. They included HCV treatment rates through March 2016 for any interferon-based or DAA-based therapies.

Read full article: Cost of Hepatitis C Antivirals May Keep Patients Away

Read Full Article: Cost of Hepatitis C Antivirals May Keep Patients Away

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.